News

December 17, 2018

Bacterial Toxin-based Test Could Help Detect Ovarian Cancer Early

News

A bacterial toxin-based blood test could help in the early detection of ovarian cancer, and function as a tool for monitoring treatment and disease progression in patients with advanced disease, ... Read more

December 14, 2018

Stanford Pursues New Research to Understand Spread and Resistance of Aggressive Ovarian Cancer

News

A team led by researchers at Stanford University will test an approach combining new materials and imaging technologies to provide a deeper understanding of how high-grade serous ovarian cancer develops. The condition is ... Read more

December 10, 2018

Bavencio Fails to Meet Primary Objectives in Certain Ovarian Cancer Patients in Phase 3 Trial

News

The immune checkpoint inhibitor Bavencio (avelumab), with or without chemotherapy, is no better than chemotherapy alone at prolonging the lives of ovarian cancer patients who failed prior platinum-based chemotherapy, results from a Phase ... Read more

December 7, 2018

OncLive’s State of the Science Summit Will Highlight Ovarian Cancer Treatments

News

OncLive’s latest State of the Science Summit will feature discussions of novel treatments for ovarian cancer and soft tissue sarcoma (STS), with presenters from the Dana-Farber Cancer Institute. To be ... Read more

December 3, 2018

AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial

News

A potential antibody treatment called AB122 enabled tumor reduction and stable disease in half of patients with ovarian cancer and other types of advanced tumors, according to early results of an ... Read more

November 30, 2018

First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors

News

A Phase 1b clinical trial studying a combination of Mirati Therapeutics‘ small molecule inhibitor sitravatinib and BeiGene‘s immune checkpoint inhibitor tislelizumab has begun dosing patients. The open-label, multicenter trial (NCT03666143), expected to include ... Read more

November 26, 2018

UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers

News

The U.K.’s National Institute of Health and Care Excellence (NICE) has decided not to recommend Lynparza (olaparib) tablets as maintenance treatment for women with relapsed ovarian cancer who respond to platinum-based chemotherapy ... Read more

November 19, 2018

Abdominal Chemotherapy Perfusion Effective on Treatment-resistant, Recurrent OC in Phase 2 Study

News

Localized chemotherapy perfusion in the abdomen showed efficacy in patients with treatment-resistant and recurrent ovarian cancer, according to preliminary results of an ongoing Phase 2 clinical study. A subset of ... Read more

November 16, 2018

FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, Merck announced ... Read more

November 12, 2018

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

News

Cristal Therapeutics has begun patient dosing in its Phase 2a trial evaluating CPC634 — the chemotherapy docetaxel, delivered in nanoparticles — in patients whose ovarian cancer has become resistant to platinum-based ... Read more